Trending Topic

Thyroid gland inside human body. 3D illustration
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Thyroid eye disease (TED), also known as Graves’ orbitopathy, is a complex autoimmune disorder driven by an interplay of immune cells, orbital fibroblasts and tissue remodelling factors that lead to inflammation, oedema and, ultimately, potential vision loss.1 While the disease has historically been challenging to manage, recent therapeutic innovations are reshaping treatment paradigms and offering new […]

Search Results

Showing Results for safety

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Thyroid eye disease (TED), also known as Graves’ orbitopathy, is a complex autoimmune disorder driven by an interplay of immune cells, orbital fibroblasts and tissue remodelling factors that lead to inflammation, oedema and, ultimately, potential vision loss.1 While the disease ...

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

Mark CompleteCompleted
BookmarkBookmarked

Coronavirus disease 2019 (COVID-19) is a life-threatening infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 Diabetes mellitus is one of the most frequent comorbidities, related to hospitalization due to SARS-CoV-2 infection, as well as a risk factor for disease severity, ...

Mark CompleteCompleted
BookmarkBookmarked

The 17th ATTD Conference (Amsterdam, 19–22 March 2025) showcased major innovations in diabetes care. The 15-day Dexcom G7 CGM proved accurate and user-friendly. The RADIANT trial showed Omnipod® 5 significantly improved glucose control over injections in type 1 diabetes. In type 2 diabetes, the 2IQP Study highlighted benefits of AID systems. Teplizumab also showed potential to enhance glycaemic stability in newly diagnosed type 1 diabetes, reinforcing the role of technology and immunotherapy in advancing diabetes management.

Mark CompleteCompleted
BookmarkBookmarked

Eneboparatide is an investigational parathyroid hormone receptor 1 (PTH1R) agonist, designed to bind with high affinity to a specific conformation of PTH1R, which is expressed in the kidneys and bone. The goal of treatment is to restore function by producing sustained and stable levels of calcium in the blood and by restoring calcium reabsorption by the kidney.2,3 Eneboparatide has been developed to have a short half-life in order to preserve bone health.

Mark CompleteCompleted
BookmarkBookmarked

Hyponatraemia is primarily a disorder of water balance or distribution, characterized by serum sodium (Nas) levels less than 135 mmol/L.1 Hyponatraemia is the most common electrolyte disorder among elderly patients and is associated with increased mortality rates and longer hospital ...

Mark CompleteCompleted
BookmarkBookmarked

Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...

Mark CompleteCompleted
BookmarkBookmarked

The 3-year results from the SURMOUNT-1 trial, published in the New England Journal of Medicine, have revealed that tirzepatide significantly reduced the risk of progression to type 2 diabetes (T2D) in individuals with obesity and prediabetes. T2D onset was ...

Mark CompleteCompleted
BookmarkBookmarked

As 2024 draws to a close, we’re celebrating a wonderful year of content.

Mark CompleteCompleted
BookmarkBookmarked
Saptarshi Bhattacharya, Sanjay Kalra, Lakshmi Nagendra

Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the ...

Mark CompleteCompleted
BookmarkBookmarked

This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained ...

Mark CompleteCompleted
BookmarkBookmarked
Sanjay Kalra, Nikhil Sharad Gokhale, Ganapathi Bantwal

Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...

Mark CompleteCompleted
BookmarkBookmarked
Mahima Chillakanti, Elaine Young, April Hopcroft

The prevalence of diabetes during pregnancy is rapidly increasing. In the USA alone, an estimated 1–2% of pregnant women have type 1 diabetes (T1D) or type 2 diabetes (T2D), and an additional 6–9% develop gestational diabetes.1 From 2000 to 2010, the prevalence of gestational ...

Mark CompleteCompleted
BookmarkBookmarked

Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...

Mark CompleteCompleted
BookmarkBookmarked

touchENDOCRINOLOGY was delighted to speak with Editorial Board member Dr Deep Dutta, a senior endocrinologist at the CEDAR Superspecialty Clinics, New Delhi, India. Throughout this interview, he summarizes the key messages from his late-breaking abstract session ‘Ailing Heart, Broken Vessels’, presented at the 60th European Association for the Study of Diabetes (EASD) annual meeting in Madrid, Spain.

Coverage from: EASD 2024

Dapiglutide is a once-weekly, subcutaneous dual GLP-1/GLP-2 receptor agonist being investigated for the treatment of obesity. This first-in-class molecule is designed to take advantage of the weight-loss effects of GLP-1 agonist and the additional benefit of a  GLP-2 agonist on improving intestinal barrier function and addressing co-morbidities associated with low-grade inflammation seen in obesity.

Coverage from: EASD 2024

After yet another successful congress, who better to reflect on the highlights than the current EASD President, Prof. Chantal Mathieu? In this interview, we explore the packed agenda, discussing everything from the prestigious prize lectures to ground-breaking research. We explore some of the most exciting data presented, including advancements in long-acting insulins, novel technologies and islet transplantation). We also touch on pivotal type 1 diabetes research (T1D), and a crucial call to action for addressing cardiovascular comorbidities in this patient population.

Load More...
Close Popup